巴利昔单抗和抗胸腺细胞球蛋白两种免疫诱导治疗在心脏死亡器官捐献肾移植中的对比

Comparison of immune-induced therapy in renal transplantation between basiliximab and ATG

目的比较巴利昔单抗和抗胸腺细胞球蛋白(ATG)在心脏死亡器官捐献(DCD)肾移植行免疫诱导治疗中的有效性和安全性。方法回顾性分析2012年1月～2018年5月在常州市第一人民医院泌尿外科应用免疫诱导剂治疗的152例肾移植患者临床资料。使用巴利昔单抗进行免疫诱导治疗的共82例,使用ATG的共70例。比较两组受者术后移植肾功能延迟恢复、急性排斥反应以及感染发生情况。结果两组1周后至1年内的血清肌酐值差异无统计学意义(P> 0.05)。巴利昔单抗组共有2例出现感染;ATG组有1例发生肺部感染,差异无统计学意义(P> 0.05)。半年后随访巴利昔单抗组80例(97.56%)肾移植存活;ATG组68例(97.14%)肾移植存活,差异无统计学意义(P> 0.05)。两组无一例死亡,均存活。结论巴利昔单抗和ATG在肾移植行免疫诱导治疗中的效果无显著差异。

Objective To compare the efficacy and safety of basiliximab and ATG in immune-induced therapy after renal transplantation. Methods The clinical data of 152 renal transplant patients treated with immune inducement in urology department of changzhou first people＇s hospital from January 2012 to May 2018 were retrospectively analyzed. A total of 82 cases were treated with basiliximab and 70 cases with ATG. Compared the incidence of postoperative DGF, AR and infection among the two group. Results Two group has no statistical significance in serum creatinine. There were 2 cases of infection in the basiliximab group, Only 1 case of wound infection occurred in the ATG group, and the distinction has no statistical significance （ χ^2=1.926, P 〉0.05）. 80 kidney transplants survived in the baliximab group and 68 kidney transplants survived in the ATG group, with no significant difference（P 〉0.05）. None of the two groups died, but survived. Conclusion There was no meaningful distinction in treatment effect between basiliximab and ATG, and there was no distinction in the incidence of infection.